Amarin's Vascepa reigns supreme in fish oil battle, as AstraZeneca's rival fizzles
AstraZeneca’s competitive threat to Amarin’s mighty Vascepa in patients with cardiovascular risk has wilted.
On Monday, the British drugmaker said it was abandoning a large cardiovascular (CV) outcomes trial testing its fish oil pill Epanova after an independent data monitoring committee predicted the therapy had a low likelihood of demonstrating a benefit to patients with mixed dyslipidaemia who carry a high risk of CV disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.